Table 1 Clinical data of patients.
Total | Total | CTC pos(%) | p-value | Total | DTC pos(%) | p-value |
|---|---|---|---|---|---|---|
376 | 84 (22) | 525 | 211 (40) | |||
Median age | 60 years (range 27–86 years) | |||||
Tumor size | ||||||
pT1 | 252 | 51 (20) | 0.37 | 329 | 127 (39) | 0.07 |
pT2-4 | 121 | 83 (43) | ||||
pT5 | 3 | 1 (33) | ||||
Nodal Status | ||||||
Node negative | 256 | 55 (21) | 0.53 | 349 | 129 (37) | 0.03 |
Node positive | 119 | 29 (24) | 174 | 82 (47) | ||
Histology | ||||||
Ductal | 289 | 65 (22) | 0.06 | 397 | 164 (41) | 0.54 |
Lobular | 47 | 15 (32) | 70 | 24 (34) | ||
Others | 40 | 4 (10) | 58 | 23 (40) | ||
Grading | ||||||
I | 75 | 13 (17) | 0.45 | 94 | 25 (27) | 0.01 |
II | 205 | 50 (24) | 277 | 118 (43) | ||
III | 96 | 21 (22) | 153 | 68 (44) | ||
Lymphangiosis | ||||||
Negative | 307 | 69 (22) | 0.92 | 418 | 159 (38) | 0.03 |
Positive | 65 | 15 (23) | 103 | 51 (50) | ||
Haemangiosis | ||||||
Negative | 371 | 84 (23) | 0.99 | 510 | 205 (40) | 0.88 |
Positive | 1 | 0 (0) | 8 | 3 (38) | ||
ER Status | ||||||
Negative | 60 | 14 (23) | 0.85 | 94 | 44(47) | 0.14 |
Positive | 315 | 70 (22) | 430 | 166 (39) | ||
PR Status | ||||||
Negative | 74 | 16 (22) | 0.86 | 136 | 66 (49) | 0.02 |
Positive | 301 | 68 (23) | 388 | 144 (37) | ||
Her2 Status | ||||||
Negative | 312 | 68 (21) | 0.22 | 438 | 170 8399 | 0.19 |
Positive | 52 | 15 (29) | 84 | 39 (46) | ||
Menopausal Status | ||||||
Premenopausal | 45 | 11 (24) | 0.75 | 72 | 35 (49) | 0.30 |
Perimenopausal | 44 | 8 (18) | 67 | 26 (39) | ||
Postmenopausal | 287 | 65 (23) | 386 | 150 (39) | ||
Immunhistochemical Subtype | ||||||
(ER−, PR−, Her2−) | 40 | 9 (23) | 0.47 | 61 | 27 (44) | 0.22 |
(ER−, PR−, Her2+) | 12 | 2 (17) | 24 | 14 (58) | ||
(ER+ and/ or PR+, Her2−) | 281 | 59 (21) | 377 | 143 (38) | ||
(ER+ and/ or PR+, Her2+) | 41 | 13 (32) | 61 | 25 (41) | ||
Bone marrow Status | ||||||
Negative | 243 | 59 (24) | 0.25 | |||
Positive | 131 | 25 (19) | ||||
Bisphosphonate Intake | ||||||
No | 254 | 58 (23) | 0.69 | 342 | 43 (13) | <0.0001 |
Yes | 119 | 25 (21) | 179 | 164 (92) | ||
